Notícias e Atualizações de Tenaya

Tenaya in selloff after early-stage data for gene therapy

Tenaya Therapeutics (NASDAQ:TNYA) lost over half its market capitalization on Tuesday after the card...

Dec 17, 2024 • Seeking Alpha

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV...

May 03, 2022 • Nasdaq

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourt...

Aug 18, 2026 • Yahoo Finance

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Dec 16, 2024 • Yahoo Finance

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated ...

Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m...

Nov 08, 2025 • Nasdaq

Alnylam’s research pact worth up to $1.1B sends Tenaya higher

Tenaya Therapeutics (TNYA) added ~10% in the premarket on Thursday after the company signed a resear...

Mar 05, 2026 • Seeking Alpha

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Aug 04, 2026 • Business Insider

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2...

May 06, 2026 • manilatimes

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne...

Apr 27, 2026 • manilatimes

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

Apr 28, 2022 • Business Wire

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

May 20, 2022 • Business Wire

Tenaya Therapeutics raises $92 million to develop gene therapies and pills for heart disease

Today, the South San Francisco–based start-up Tenaya Therapeutics announced that it raised $92 mil...

Oct 02, 2019 • C&EN

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of...

Jan 13, 2025 • Stockhouse

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develo...

May 10, 2022 • The Globe and Mail

TNYA Tenaya Therapeutics, Inc.

7 analysts have issued ratings. Wall Street analysts rate TNYA as Very Bullish on average, for a Wal...

Dec 03, 2025 • Seeking Alpha

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Dem...

Aug 05, 2026 • Yahoo Finance

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T...

Mar 02, 2026 • Yahoo Finance

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including ...

Aug 07, 2026 • The Globe and Mail

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Oct 26, 2023 • Yahoo Finance

Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration

Tenaya Therapeutics ( (TNYA)) just unveiled an update. On March 4, 2026, Tenaya Therapeutics entered...

Mar 03, 2026 • The Globe and Mail

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNY...

Jul 14, 2026 • Business Insider

Tenaya Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026

Tenaya Therapeutics, Inc. a communiqué ses résultats financiers pour le deuxième trimestre et le ...

Aug 05, 2026 • Zonebourse

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed

Earlier this week, Tenaya Therapeutics reported encouraging interim data from its RIDGE-1 trial of T...

Dec 14, 2025 • Yahoo Finance

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Jun 29, 2026 • Business Insider

Tenaya, Alnylam in Cardiovascular Disease Research Collaboration Worth Up to $1.14B

Tenaya Therapeutics and Alnylam Pharmaceuticals are collaborating on research to find treatments for...

Mar 05, 2026 • MarketWatch

Tenaya Names Eric Hyllengren as CFO

Hyllengren has more than two decades of experience in biotechnology finance, capital markets and cor...

Jun 29, 2026 • MarketWatch

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnol...

Nov 21, 2021 • Nasdaq

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutic...

Mar 09, 2026 • Yahoo Finance

Tenaya Therapeutics Ends Manufacturing Center Lease, Shifts Strategy

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including ch...

Jun 28, 2026 • The Globe and Mail

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits...

Jun 03, 2026 • Markets Insider